AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 282 min read$KIDS

OrthoPediatrics Q3 Earnings Call Highlights

OrthoPediatrics (KIDS) reported Q3 revenue growth, with scoliosis revenue up 18% to $19.2M. The company surpassed 1,000 PNP tibial nail implantations and plans a full commercial release for PNP Retrograde in mid-2027. OPSB segment grew over 20%, with 60+ clinics. Gross margin remained at 74%, while GAAP net loss narrowed to $0.25 per share. The company raised full-year 2026 revenue guidance to $270M-$273M and expects positive free cash flow in 2027.

Original reporting
finance.yahoo.com
Published Oct 28, 2026, 12:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 12:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
OrthoPediatrics Q3 Earnings Call Highlights — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$KIDSBullishMed
01

Why it matters

The raised revenue guidance and positive cash‑flow outlook may attract growth‑oriented investors, while higher SG&A expenses could temper enthusiasm.

02

Market read

Earnings release with new guidance is a primary market‑moving event for KIDS and its sector.

03

What to watch

Potential supply‑chain constraints for new product launches and reliance on FDA approvals.

Relevance 7/10Novelty 7/10Timing: after-hours

Background

OrthoPediatrics (NASDAQ:KIDS) provides pediatric orthopedic implants and orthoses. The Q3 call disclosed product milestones, margin stability, and a cash‑flow breakeven target.

Company-level read

Ticker impact

$KIDSBullishHigh confidence
Context

OrthoPediatrics reported Q3 results, raised full-year 2026 revenue guidance to $270‑$273M and reaffirmed EBITDA outlook.

Expected impact

likely upward pressure as investors price in higher revenue expectations

Evidence & confidence

Guidance lift and positive cash‑flow outlook are fresh, material facts that can move the share price.

Market effects

Sector

May boost sentiment for pediatric orthopedic device makers and related med‑tech peers.

Regional

Limited to U.S. and North American healthcare investors.

Global

Low; impact confined to niche medical device sector.

Counterpoint

What could challenge this read

Guidance raise could be offset by higher operating expenses and a cautious outlook for Q4 sales.

Key entities

  • company
    OrthoPediatrics Corp.

    Medical device company focused on pediatric orthopedics.

  • executive
    Bailey

    CEO providing commentary on product launches and outlook.

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 27
$KIDSHighAI 8/10

OrthoPediatrics (KIDS) Q3 2026 Earnings Call Transcript

OrthoPediatrics (KIDS) reported Q3 2026 revenue of $727M, up 19% YoY, and raised full-year guidance to $270M-$273M. Growth was driven by legacy products, implant demand, and international sales. The company highlighted progress in its innovation super cycle, with new products like 3P Hip, Traxeo, and VerteGlide contributing to performance. Adjusted EBITDA and free cash flow were record highs, with plans to maintain positive cash flow in 2027.

finance.yahoo.com3 min
OCT 27
$KIDSHighAI 8/10

OrthoPediatrics receives FDA clearance for femur nail system

OrthoPediatrics (KIDS) received FDA clearance for its Pediatric Nailing Platform Femur Retrograde Nail System, designed for pediatric trauma and deformity correction. The system is available in diameters from 7 mm to 11 mm and will be released in 2026, with broader commercialization in 2027. The company has used its Pediatric Nailing Platform in approximately 15,000 patients worldwide.

investing.com2 min
OCT 27
$KIDSHigh

OrthoPediatrics Corp. Reports Third Quarter 2026 Financial Results and Increases 2026 Financial Guidance Record Third Quarter 2026 Revenue of $72.7 Million…

ORTHOPEDIATRICS CORP (KIDS) filed an SEC Form 8-K — Results of Operations and Financial Condition. OrthoPediatrics Corp. Reports Third Quarter 2026 Financial Results and Increases 2026 Financial Guidance Record Third Quarter 2026 Revenue of $72.7 Million, Up 19% Year-over-Year WARSAW, Ind., October 27, 2026 -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq:

SEC EDGAR 8-K2 min
SEP 11
$KIDSHighAI 8/10

OrthoPediatrics (KIDS) Crosses $70M as Guidance Climbs Higher

OrthoPediatrics (KIDS) reported Q2 revenue of $70.5M, up 15% YoY, and raised 2026 guidance to $265M-$269M. Trauma and Deformity revenue grew 26%, while international sales rose 22%. Despite higher expenses, gross margin expanded to 74% and adjusted EBITDA doubled to $6.8M. Net loss remained at $7.2M, and cash reserves declined to $47.9M.

insidermonkey.com2 min
AUG 6
$KIDSMed

OrthoPediatrics Corp. Q2 2026 Earnings Call Summary

OrthoPediatrics reported Q2 2026 progress toward a “financial inflection point,” citing record adjusted EBITDA margins near 10% and a shift toward positive free cash flow. Trauma and Deformity revenue grew 26% on implant share gains and early 3P Hip deployments. Management expects positive free cash flow in H2 2026 and FCF break-even or better for full-year 2026, with conservative timing assumptions for capital placements and international orders.

yahoo.com7 min
AUG 4
$KIDSMed

OrthoPediatrics Corp. Reports Second Quarter 2026 Financial Results and Increases 2026 Financial Guidance

ORTHOPEDIATRICS CORP (KIDS) filed an SEC Form 8-K — Results of Operations and Financial Condition. OrthoPediatrics Corp. Reports Second Quarter 2026 Financial Results and Increases 2026 Financial Guidance Second Quarter 2026 Revenue Surpasses $70 million for the First Time in Company History, and Increased 15% Year-over-Year WARSAW, Ind., August 4, 2026 -- OrthoPediatrics Corp

SEC EDGAR 8-K6 min